Clinical Trial Update: AZD0530 to Treat Recurrent Stage IIIB/IV NSCLC Previously Treated With Combination Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial update for AZD0530 in recurrent stage IIIB/IV non-small cell lung cancer previously treated with chemotherapy; status completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD0530 (saracatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2015-07-14